Innate Pharma (NASDAQ:IPHA – Get Free Report) was downgraded by investment analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a report issued on Thursday, MarketBeat reports. They currently have a $1.00 price target on the stock. Leerink Partners‘s price target would suggest a potential downside of 2.91% from the stock’s current price.
Several other research analysts also recently commented on the stock. UBS Group reissued a “buy” rating on shares of Innate Pharma in a report on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Innate Pharma in a research report on Tuesday, September 22nd. HC Wainwright reiterated a “buy” rating on shares of Innate Pharma in a research report on Monday, September 21st. Citigroup raised Innate Pharma from a “buy” rating to an “outperform” rating in a research note on Tuesday, August 11th. Finally, BTIG Research restated a “buy” rating on shares of Innate Pharma in a research report on Thursday, November 5th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $5.67.
View Our Latest Report on Innate Pharma
Innate Pharma Stock Down 22.6%
Shares of NASDAQ:IPHA opened at $1.03 on Thursday. The company has a 50 day moving average of $1.57 and a 200 day moving average of $1.69. Innate Pharma has a 12 month low of $1.00 and a 12 month high of $2.71.
Innate Pharma Company Profile
Innate Pharma is a clinical-stage biotechnology company based in Marseille, France. It develops immunotherapies for cancer, with research focused on harnessing the body’s innate immune system to recognize and attack tumor cells. The company’s work includes antibody-based treatments and cell therapies, with investigational candidates being studied for blood cancers and other malignancies. Its pipeline includes lacutamab, an antibody candidate targeting KIR3DL2, and programs developed with pharmaceutical partners.
Recommended Stories
- Five stocks we like better than Innate Pharma
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
